Accéder directement au contenu Accéder directement à la navigation
Article dans une revue

Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials

Thomas Aparicio 1, 2, * Michel Ducreux 3, 4 Roger Faroux 5 Emilie Barbier 6, 7 Sylvain Manfredi 8, 7, 9 Thierry Lecomte 10 Pierre-Luc Etienne 11 Laurent Bedenne 9, 8, 7 Jaafar Bennouna 12 Jean-Marc Phélip 13, 14 Eric François 15 Pierre Michel 16 Jean-Louis Legoux 17 Mohamed Gasmi 18 Gilles Breysacher 19 Philippe Rougier 20 Aimery de Gramont 21 Come Lepage 8, 7, 9 Olivier Bouché 22 Jean-François Seitz 23 - For Ffcd Investigators A Adenis A Alessio A Aouakli A Azzedine A Bedjaoui A Bidault A Blanchi A Botton A Cadier-Lagnes A Fatisse A Gagnaire A Gilbert A Gueye A Hollebecque A Lemaire A Mahamat A Marre A Patenotte A Rotenberg A Roussel A Thirot-Bidault A Votte A Weber A Zaanan Ac Dupont-Gossart Al Villing Am Queuniet B Coudert B Denis B Garcia B Lafforgue B Landi B Leduc B Linot B Paillot B Rhein B Winkfield C Barberis C Becht C Belletier C Berger C Bineau C Borel C Brezault C Buffet C Cornila C Couffon C de la Fouchardière C Giraud C Lecaille C Lepere C Lobry C Locher C Lombard-Bohas C Paoletti C Platini C Rebischung C Sarda C Vilain C Briac-Levaché D Auby D Baudet-Klepping D Bechade D Besson D Cleau D Festin D Gargot D Genet D Goldfain D Luet D Malka D Peré-Vergé D Pillon D Sevin-Robiche D Smith D Soubrane D Tougeron D Zylberait E Carola E Cuillerier E Dorval Danquechin E Echinard E Janssen E Maillard E Mitry E Norguet-Monnereau E Suc E Terrebonne E Zrihen Ea Pariente F Almaric F Audemar F Bonnetain F Desseigne F Dewaele F Di Fiore F Ghiringhelli F Husseini F Khemissa F Kikolski F Morvan F Petit-Laurent F Riot F Subtil F Zerouala-Boussaha Fx Caroli-Bosc G Boilleau-Jolimoy G Bordes G Cavaglione G Coulanjon G Deplanque G Gatineau-Saillant G Goujon G Medinger G Roquin H Brixi-Benmansour H Castanie H Lacroix H Maechel H Perrier H Salloum H Senellart I Baumgaertner I Cumin I Graber I Trouilloud J Boutin J Butel J Charneau J Cretin J Dauba J Deguiral J Egreteau J Ezenfis J Forestier J Goineau J Lacourt J Lafon J Martin J Meunier J Moreau J Provencal J Taieb J Thaury J Tuaillon J Vergniol J Villand J Vincent J Volet Jb Bachet Jc Barbare Jc Souquet Jd Grangé Jf Dor Jf Paitel Jl Jouve Jl Raoul Jm Cheula Jm Gornet Jm Sabate Jm Vantelon Jn Vaillant Jp Aucouturier Jp Barbieux Jp Herr Jp Lafargue Jp Lagasse Jp Latrive Jp Plachot Jp Ramain Jp Robin Jp Spano Jy Douillard K Beerblock K Bouhier-Leporrier K Slimane Fawzi L Cany L Chone L Dahan L Gasnault L Rob L Wander M Baconnier M Ben Abdelghani M Benchalal M Blasquez M Carreiro M Charbit M Combe M Duluc M Fayolle M Gignoux M Giovannini M Glikmanas M Mabro M Mignot M Mornet M Mousseau M Mozer M Pauwels M Pelletier M Porneuf M Ramdani M Schnee M Tissot M Zawadi Mc Clavero-Fabri Mc Gouttebel Mc Kaminsky Mp Galais N Abdelli N Barrière N Bouaria N Bouarioua N Delas N Gérardin N Hess-Laurens N Stremsdoerfer O Berthelet O Boulat O Capitain O Favre P Amoyal P Bergerault P Burtin P Cassan P Chatrenet P Chiappa P Claudé P Couzigou P Feydy P Follana P Geoffroy P Godeau P Hammel P Laplaige P Lehair P Martin P Novello P Pantioni P Pienkowski P Pouderoux P Prost P Ruszniewski P Souillac P Texereau P Thévenet Pa Haineaux R Benoit R Coriat R Lamy R Mackiewicz S Beorchia S Chaussade S Hiret S Jacquot S Lavau Denes S Montembault S Nahon S Nasca S Nguyen S Oddou-Lagraniere S Pesque-Penaud Sp Fratte T Chatellier T Mansourbakht T Morin T Walter V Boige V Bourgeois V Derias V Guérin-Meyer V Hautefeuille V Jestin Le Tallec V Lorgis V Quentin V Sebbagh V Veuillez X Adhoute X Coulaud Y Becouarn Y Coscas Y Courouble Y Le Bricquir Y Molin Y Rinaldi Yh Lam Z. Ladhib
* Auteur correspondant
1 Service d'hépato-gastro-entérologie [Hôpital Saint-Louis]
2 USPC - Université Sorbonne Paris Cité
3 Université Paris-Saclay
4 Oncologie digestive
Département de médecine oncologique [Gustave Roussy]
5 Service de gastroentérologie (CHD Vendee - Hopital Les Oudairies, La Roche Sur Yon)
6 Fédération Francophone de la Cancérologie Digestive, FFCD
7 LNC - Lipides - Nutrition - Cancer [Dijon - U1231]
8 UBFC - Université Bourgogne Franche-Comté [COMUE]
9 Service d'Hépato-Gastro-Entérologie (CHU de Dijon)
10 Département d'hépato-gastro-entérologie [Hôpital Trousseau : CHRU Tours]
11 HPCA - Hôpital Privé des Côtes d'Armor
12 UNICANCER/ICO - Institut de Cancérologie de l'Ouest [Angers/Nantes]
13 Service de gastroentérologie [CHU Saint-Etienne]
14 Institut de Cancérologie de la Loire [Saint-Priest en Jarez]
15 UNICANCER/CAL - Centre de Lutte contre le Cancer Antoine Lacassagne [Nice]
16 Service d'Hépato-Gastroentérologie [CHU Rouen]
17 Service d'hépato-gastro-entérologie et oncologie digestive [CHR Orléans]
18 Service De Gastroenterologie, Hôpital Nord, Assistance Publique-Hôpitaux de Marseille
19 CH Colmar - Hôpital Louis Pasteur [Colmar]
20 Département d'hépato-gastro-entérologie [CHU Nantes]
21 Service d'oncologie [Institut Hospitalier Franco-Britannique : Levallois-Perret]
22 Département d'oncologie médicale (CHU Robert Debré, Reims)
23 Service d'oncologie digestive et hépato-gastro-entérologie [Hôpital de la Timone - APHM]
Abstract : BACKGROUND: Previous studies showed that high and low body mass index (BMI) was associated with worse prognosis in early-stage colorectal cancer (CRC), and low BMI was associated with worse prognosis in metastatic CRC (mCRC). We aimed to assess efficacy outcomes according to BMI. PATIENTS AND METHODS: A pooled analysis of individual data from 2085 patients enrolled in eight FFCD first-line mCRC trials from 1991 to 2013 was performed. Comparisons were made according to the BMI cut-off: Obese (BMI ≥30), overweight patients (BMI ≥ 25), normal BMI patients (BMI: 18.5-24) and thin patients (BMI <18.5). Interaction tests were performed between BMI effect and sex, age and the addition of antiangiogenics to chemotherapy. RESULTS: The rate of BMI ≥25 patients was 41.5%, ranging from 37.6% (1991-1999 period) to 41.5% (2000-2006 period) and 44.8% (2007-2013 period). Comparison of overweight patients versus normal BMI range patients revealed a significant improvement of median overall survival (OS) (18.5 versus 16.3 months, HR = 0.88 [0.80-0.98] p = 0.02) and objective response rate (ORR) (42% versus 36% OR = 1.23 [1.01-1.50] p = 0.04) but a comparable median progression-free survival (PFS) (7.8 versus 7.2 months, HR = 0.96 [0.87-1.05] p = 0.35). Subgroup analyses revealed that overweight was significantly associated with better OS in men. OS and PFS were significantly shorter in thin patients. CONCLUSION: Overweight patients had a prolonged OS compared with normal weight patients with mCRC. The association of overweight with better OS was only observed in men. The pejorative prognosis of BMI <18.5 was confirmed. Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved
Keywords : Prognostic factor Pooled analysis Bevacizumab Colorectal cancer Overweight
Type de document :
Article dans une revue
Liste complète des métadonnées
https://hal-univ-bourgogne.archives-ouvertes.fr/hal-01983308
Contributeur : Lnc - Université de Bourgogne <>
Soumis le : mercredi 16 janvier 2019 - 12:41:38
Dernière modification le : mercredi 19 août 2020 - 12:08:20

Lien texte intégral

openaccess

Identifiants

Collections

UNIV-BOURGOGNE | LNC-EPICAD | ICO | FNCLCC | LNC-UMR866 | COMUE-NORMANDIE | UNIROUEN | UNIV-PARIS-SACLAY | IGR

Citation

Thomas Aparicio, Michel Ducreux, Roger Faroux, Emilie Barbier, Sylvain Manfredi, et al.. Overweight is associated to a better prognosis in metastatic colorectal cancer: A pooled analysis of FFCD trials. European Journal of Cancer, Elsevier, 2018, 98, pp.1-9. ⟨10.1016/j.ejca.2018.03.031⟩. ⟨hal-01983308⟩

Exporter

BibTeX TEI DC DCterms EndNote

Partager

Métriques

Consultations de la notice

144